China Meheco subsidiary obtains drug registration certificate

China Meheco announced that its wholly-owned subsidiary, Tianfang Pharmaceutical, has been granted registration certificates from the National Medical Products Administration for its Urapidil Hydrochloride Injection. This drug is primarily used for treating hypertensive emergencies, severe and very severe hypertension, and refractory hypertension, as well as for controlling perioperative hypertension. The National Medical Products Administration accepted the registration application in February 2024. As of the announcement date, the total R&D investment in the drug’s raw materials and formulations was approximately CNY 7.31 million. China Meheco notes that domestic sales for Urapidil Hydrochloride Injection totaled approximately CNY 1.72 billion in 2023 and CNY 8.01 billion in 2024, but cautions that future sales may not meet expectations due to market uncertainties.